TW446704B - Naphtho[2,3-B]heteroar-4-yl derivatives for treating metabolic disorders related to insulin resistance or hyperglycemia - Google Patents

Naphtho[2,3-B]heteroar-4-yl derivatives for treating metabolic disorders related to insulin resistance or hyperglycemia Download PDF

Info

Publication number
TW446704B
TW446704B TW088107606A TW88107606A TW446704B TW 446704 B TW446704 B TW 446704B TW 088107606 A TW088107606 A TW 088107606A TW 88107606 A TW88107606 A TW 88107606A TW 446704 B TW446704 B TW 446704B
Authority
TW
Taiwan
Prior art keywords
dimethyl
compound
hydrogen
alkyl
pharmaceutically acceptable
Prior art date
Application number
TW088107606A
Other languages
English (en)
Chinese (zh)
Inventor
Paul Jeffrey Dollings
Arlene Joan Dietrich
Jay Edward Wrobel
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Application granted granted Critical
Publication of TW446704B publication Critical patent/TW446704B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74—Naphthothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW088107606A 1998-05-12 1999-05-11 Naphtho[2,3-B]heteroar-4-yl derivatives for treating metabolic disorders related to insulin resistance or hyperglycemia TW446704B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7644698A 1998-05-12 1998-05-12

Publications (1)

Publication Number Publication Date
TW446704B true TW446704B (en) 2001-07-21

Family

ID=22132072

Family Applications (1)

Application Number Title Priority Date Filing Date
TW088107606A TW446704B (en) 1998-05-12 1999-05-11 Naphtho[2,3-B]heteroar-4-yl derivatives for treating metabolic disorders related to insulin resistance or hyperglycemia

Country Status (8)

Country Link
EP (1) EP1077968A1 (fr)
JP (1) JP2002514639A (fr)
CN (1) CN1308625A (fr)
AR (1) AR019842A1 (fr)
AU (1) AU3791699A (fr)
CA (1) CA2330555A1 (fr)
TW (1) TW446704B (fr)
WO (1) WO1999058522A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60124861T2 (de) 2000-01-21 2007-05-10 Novartis Ag Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
WO2003048140A1 (fr) 2001-12-03 2003-06-12 Japan Tobacco Inc. Compose azole et utilisation medicinale de celui-ci
US7226915B2 (en) * 2003-05-15 2007-06-05 Hoffmann-La Roche Inc. Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors
CN100334088C (zh) * 2003-05-15 2007-08-29 霍夫曼-拉罗奇有限公司 作为蛋白质酪氨酸磷酸酶抑制剂的二氨基吡咯并喹唑啉化合物
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2005035551A2 (fr) 2003-10-08 2005-04-21 Incyte Corporation Inhibiteurs de proteines se liant a des molecules phosphorylees
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2007033266A2 (fr) 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Administration d'inhibiteurs de dipeptidyl peptidase
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2170930B3 (fr) 2007-06-04 2013-10-02 Synergy Pharmaceuticals Inc. Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2011041293A1 (fr) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Dérivés pyrazolo [1, 5—a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose
CN102834393B (zh) 2010-02-03 2015-07-22 武田药品工业株式会社 细胞凋亡信号调节激酶1抑制剂
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9486433B2 (en) 2012-10-12 2016-11-08 Mochida Pharmaceuticals Co. Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US9828345B2 (en) 2013-02-28 2017-11-28 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
WO2014142364A2 (fr) 2013-03-15 2014-09-18 Mochida Pharmaceutical Co., Ltd. Compositions et méthodes de traitement de la stéatohépatite non alcoolique
WO2014151206A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
CA2905435A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
EP3004138B1 (fr) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Agonistes ultra-purs de guanylate cyclase c, leur procédé de production et d'utilisation
CN106749169B (zh) * 2016-11-07 2020-04-21 浙江工业大学 一种Ertiprotafib的手性制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE154935T1 (de) * 1993-06-14 1997-07-15 Pfizer Zweite amine als antidiabetische mittel und für die behandlung von fettleibigkeit
US5747527A (en) * 1995-06-06 1998-05-05 Shaman Pharmaceuticals, Inc. Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
CA2227691A1 (fr) * 1995-08-28 1997-03-06 American Home Products Corporation Acides phenoxyacetiques en tant qu'inhibiteurs de l'aldose reductase et agents anti-hyperglycemiants

Also Published As

Publication number Publication date
CN1308625A (zh) 2001-08-15
WO1999058522A1 (fr) 1999-11-18
AR019842A1 (es) 2002-03-20
AU3791699A (en) 1999-11-29
EP1077968A1 (fr) 2001-02-28
CA2330555A1 (fr) 1999-11-18
JP2002514639A (ja) 2002-05-21

Similar Documents

Publication Publication Date Title
TW446704B (en) Naphtho[2,3-B]heteroar-4-yl derivatives for treating metabolic disorders related to insulin resistance or hyperglycemia
JP4482513B2 (ja) Ｎ２−（置換アリールメチル）−３−（置換フェニル）インダゾールおよびこれを含む抗血管形成剤
JP5244091B2 (ja) Ｅｐ４受容体アンタゴニストとしてのインドールアミド誘導体
RU2515968C2 (ru) 5-членное гетероциклическое соединение и его применение для лекарственных целей
AU2013366898B2 (en) Halogen-substituted heterocyclic compound
CN101772487B (zh) 甲状腺类化合物
US20120238588A1 (en) 1H-Pyrrolo[2,3-B]Pyridines
CN101133037B (zh) 六元杂环化合物及其用途
TWI304805B (en) New retinoids for the treatment of emphysema
WO2007015744A1 (fr) Composés thiényl bi-substitués et leur utilisation en tant que produits pharmaceutiques
JP2009516694A (ja) 化合物
TW200400183A (en) 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same
JP2009516746A (ja) 化合物
JP2009516695A (ja) 化合物
TW201010977A (en) Amide compound
MXPA06001739A (es) Derivado de acido arilalcanoico substituido y uso del mismo.
CN101370380A (zh) 化合物
IL31246A (en) Phenylethananolamine compounds, their preparations and veterinary medicinal products containing them
CA2904160A1 (fr) Derives de sulfonamide phenyle et leur utilisation dans le traitement del'arthrite
CA1229047A (fr) Derives de benzothiophene utilises comme agents antiasthmatiques
CN104109115B (zh) 一种含氮杂环链接的苯丙酸类化合物、其药物组合物、制备方法和用途
KR970011580B1 (ko) 항알레르기 활성을 갖는 신규의 벤조티오펜
JP2001512113A (ja) 抗腫瘍及び抗転移剤としてのｏ−置換ヒドロキシクマラノン誘導体
US20160280671A1 (en) Compositions for the treatment of hypertension and/or fibrosis
US20170128434A1 (en) Novel estrogen receptor ligands

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees